Earlier this month, the results of the phase-three study of vosoritide, the drug Samuel takes, were published in the medical journal the Lancet (the previous phase established that it was safe). Covering several countries, with 119 children taking part, it found that those taking the drug for a year grew faster than those on a placebo. “The main purpose of the drug is to improve the quality of life for children with achondroplasia,” says Irving. She knows that a drug treatment is “nothing like leg-lengthening, but it’s about why people are doing this. ‘The decision to take part in the trial was purely based on improving Samuel’s quality of life.’ Samuel with his mum, Kristina, and Hamish.

Source: The Guardian September 28, 2020 04:52 UTC